ArticleFrontiers in oncology2021
Case Report and Literature Review: Primary Pulmonary NUT-Midline Carcinoma.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Anti-angiogenic therapy as a beacon of hope in the battle against pulmonary NUT midline carcinoma.Frontiers of medicine · 2025Pooled it
- Primary pulmonary nuclear protein of the testis midline carcinoma: case report and systematic review with pooled analysis.Frontiers in oncology · 2023Pooled it
- International guidelines on the diagnosis and treatment of NUT carcinoma.Innovation (Cambridge (Mass.)) · 2026Review
- Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- A Prompt Diagnosis and Treatment of a Case of Nuclear Protein of the Testis Carcinoma Characterized by a Bronchial Lesion and High Serum Alpha-fetoprotein Level Following Genomic Testing.Internal medicine (Tokyo, Japan) · 2024Article
- Consolidation immunotherapy following concurrent chemoradiotherapy in a patient with sinonasal NUT carcinoma: a case report.Frontiers in oncology · 2024Article
- Prolonged Survival of NUT Midline Carcinoma and Current Approaches to Treatment.The oncologist · 2023Article
- Clinical and molecular features of pulmonary NUT carcinoma characterizes diverse responses to immunotherapy, with a pathologic complete response case.Journal of cancer research and clinical oncology · 2023Article
- Molecular features driving condensate formation and gene expression by the BRD4-NUT fusion oncoprotein are overlapping but distinct.Scientific reports · 2023Article
- Molecular features driving condensate formation and gene expression by the BRD4-NUT fusion oncoprotein are overlapping but distinct.bioRxiv : the preprint server for biology · 2023Article
- Clinicopathological molecular characterizations of sinonasal NUT carcinoma: a report of two cases and a literature review.Frontiers in oncology · 2023Article
- Multimodality imaging and treatment of paranasal sinuses nuclear protein in testis carcinoma: A case report.World journal of clinical cases · 2022Article
- Diagnosis, Treatment and Prognosis of Primary Pulmonary NUT Carcinoma: A Literature Review.Current oncology (Toronto, Ont.) · 2022Review
- Clinical imaging of primary pulmonary nucleoprotein of the testis carcinoma.Frontiers in medicine · 2022Article
- Primary Thyroid NUT Carcinoma With High PD-L1 Expression and Novel MassiveFrontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nuclear protein of the testis (NUT) carcinoma is a very rare and aggressive carcinoma characterized by chromosomal rearrangement. NUT-midline carcinoma (NMC) can occur anywhere in the body, but most of the tumors are found in the midline anatomic structure or mediastinum. Pulmonary-originated NMC is extremely rare and often difficult to be distinguished from other poorly differentiated tumors, making the diagnosis awfully challenged in clinical practice. There are less than 100 cases of NUT carcinoma reported so far. In this study, the diagnosis and molecular mechanisms of reported NUT carcinoma cases were reviewed. Furthermore, a case of primary pulmonary NUT-midline carcinoma and its pathological features was reported. The process of pathological identification and genomic analysis for establishing the diagnosis was discussed. We found that NUT carcinoma could be identified by combining CT, H&E staining, immunohistochemistry (IHC), and molecular tests. The development of NUT carcinoma might be associated with mutation of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.